Natera's (NTRA) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Natera's stock has been reaffirmed with a "sell (D-)" rating by Weiss Ratings.
• Analysts maintain a generally positive outlook, with several firms issuing buy ratings and price targets ranging from $183.00 to $268.00.
• Natera reported revenue growth of 32.2% compared to the previous year, though it missed earnings expectations for the last quarter.

Natera (NASDAQ:NTRA - Get Free Report)'s stock had its "sell (d-)" rating restated by Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

Other research analysts also recently issued research reports about the stock. Morgan Stanley restated an "overweight" rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Canaccord Genuity Group reiterated a "buy" rating and issued a $200.00 price objective on shares of Natera in a report on Tuesday, October 14th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Piper Sandler reissued an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. Finally, Stephens reaffirmed an "overweight" rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $197.59.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $192.51 on Friday. The business has a 50 day simple moving average of $171.29 and a two-hundred day simple moving average of $160.37. Natera has a 1 year low of $117.27 and a 1 year high of $198.99. The firm has a market capitalization of $26.42 billion, a PE ratio of -100.79 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera's quarterly revenue was up 32.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts expect that Natera will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of Natera stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $137.40, for a total value of $418,383.00. Following the completion of the sale, the chief financial officer directly owned 65,430 shares in the company, valued at $8,990,082. The trade was a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $132.89, for a total transaction of $398,670.00. Following the completion of the transaction, the insider directly owned 123,059 shares in the company, valued at approximately $16,353,310.51. This represents a 2.38% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,446 shares of company stock worth $11,207,899. 5.63% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in the company. HighPoint Advisor Group LLC raised its position in shares of Natera by 30.8% in the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after acquiring an additional 468 shares during the period. Park Avenue Securities LLC bought a new position in shares of Natera in the second quarter valued at $1,525,000. Amalgamated Bank boosted its holdings in shares of Natera by 9.8% during the 1st quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after buying an additional 740 shares during the period. Comerica Bank boosted its holdings in shares of Natera by 24.1% during the 1st quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock worth $19,954,000 after buying an additional 27,379 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after buying an additional 207 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.